GeneDx (US:WGS)2025-07-29 12:30Financial Performance - GeneDx grew revenues to $102.7 million, a 49% increase year-over-year[25] - Exome and genome test revenue grew to $85.9 million, a 69% increase year-over-year[25] - The company delivered an adjusted gross margin of 71%, up from 62% in the second quarter of 2024[25] - Adjusted net income was $15.0 million in the second quarter of 2025[25] - Cash, cash equivalents, marketable securities, and restricted cash totaled $135.5 million as of June 30, 2025[39] Volume and Market Share - Exome and genome volume grew 28% year-over-year in Q2 2025[34] - The mix share for exome and genome tests grew to 41%[34] Guidance - The company updated its full-year 2025 revenue guidance to $400 to $415 million, from $360 to $375 million[40] - The company expects growth in exome and genome revenue of 48% to 52%[40] - The company expects growth in exome and genome volume of 30%[40] - The company expects adjusted gross margin of 68% to 71%[40]